Last reviewed · How we verify
Prednisone continuation
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Inflammatory and autoimmune disorders, Allergic reactions, Certain malignancies (as adjunctive therapy).
At a glance
| Generic name | Prednisone continuation |
|---|---|
| Sponsor | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Prednisone acts as a glucocorticoid receptor agonist, inhibiting the production and release of pro-inflammatory cytokines and reducing immune cell activation. It decreases capillary permeability, stabilizes lysosomal membranes, and suppresses both humoral and cell-mediated immune responses. This broad immunosuppressive and anti-inflammatory action makes it effective across multiple therapeutic areas.
Approved indications
- Inflammatory and autoimmune disorders
- Allergic reactions
- Certain malignancies (as adjunctive therapy)
- Adrenal insufficiency
- Respiratory conditions with inflammation
Common side effects
- Increased infection risk
- Hyperglycemia
- Osteoporosis
- Hypertension
- Mood changes
- Insomnia
- Gastrointestinal upset
- Weight gain
Key clinical trials
- Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression (PHASE3)
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (PHASE2, PHASE3)
- Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) (PHASE1, PHASE2)
- A Study in Adults With Untreated Acute Lymphoblastic Leukemia (PHASE2)
- PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma (PHASE2)
- Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) (PHASE3)
- LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis (PHASE2, PHASE3)
- H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: